Skip to main content
Top
Published in: International Urology and Nephrology 6/2013

01-12-2013 | Urology - Original Paper

Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy

Authors: Luciano Macchione, Giuseppe Mucciardi, Alessandro Gali’, Antonina Di Benedetto, Salvatore Butticè, Carlo Magno

Published in: International Urology and Nephrology | Issue 6/2013

Login to get access

Abstract

The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.
Literature
1.
go back to reference Fitzpatrick JM (2006) The natural history of benign prostatic hyperplasia. BJU Int 97(Suppl 2):3–6; discussion 21-2 Fitzpatrick JM (2006) The natural history of benign prostatic hyperplasia. BJU Int 97(Suppl 2):3–6; discussion 21-2
2.
go back to reference Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50:969–980PubMedCrossRef Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50:969–980PubMedCrossRef
3.
go back to reference Rieken M, Ebinger Mundorff N, Bonkat G, Wyler S, Bachmann A (2010) Complications of laser prostatectomy: a review of recent data. World J Urol 28(1):53–62PubMedCrossRef Rieken M, Ebinger Mundorff N, Bonkat G, Wyler S, Bachmann A (2010) Complications of laser prostatectomy: a review of recent data. World J Urol 28(1):53–62PubMedCrossRef
4.
go back to reference Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ (2010) Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol 28(1):45–51PubMedCrossRef Herrmann TR, Bach T, Imkamp F, Georgiou A, Burchardt M, Oelke M, Gross AJ (2010) Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol 28(1):45–51PubMedCrossRef
5.
go back to reference Szlauer R, Gotschl R, Razmaria A, Paras L, Schmeller NT (2009) Endoscopic vaporesection of the prostate using the continuous-wave 2-mm thulium laser: outcome and demonstration of the surgical technique. Eur Urol 55(2):368–375PubMedCrossRef Szlauer R, Gotschl R, Razmaria A, Paras L, Schmeller NT (2009) Endoscopic vaporesection of the prostate using the continuous-wave 2-mm thulium laser: outcome and demonstration of the surgical technique. Eur Urol 55(2):368–375PubMedCrossRef
6.
go back to reference Fu WJ, Zhang X, Yang Y, Hong BF, Gao JP, Cai W, Zhang P, Wang XX (2010) Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up. Urology 75(1):194–199PubMedCrossRef Fu WJ, Zhang X, Yang Y, Hong BF, Gao JP, Cai W, Zhang P, Wang XX (2010) Comparison of 2-microm continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective nonrandomized trial with 1-year follow-up. Urology 75(1):194–199PubMedCrossRef
7.
go back to reference Gupta N, Kumar R, Dogra PN, Seth A (2006) Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 97(1):85–89PubMedCrossRef Gupta N, Kumar R, Dogra PN, Seth A (2006) Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int 97(1):85–89PubMedCrossRef
8.
go back to reference Fu WJ, Gao JP, Hong BF, Yang Y, Cai W, Zhang L (2008) Photoselective laser vaporization prostatectomy for acute urinary retention in China. J Endourol 22(3):539–543PubMedCrossRef Fu WJ, Gao JP, Hong BF, Yang Y, Cai W, Zhang L (2008) Photoselective laser vaporization prostatectomy for acute urinary retention in China. J Endourol 22(3):539–543PubMedCrossRef
9.
go back to reference Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ (2007) RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 25(3):257–262PubMedCrossRef Bach T, Herrmann TR, Ganzer R, Burchardt M, Gross AJ (2007) RevoLix vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up. World J Urol 25(3):257–262PubMedCrossRef
10.
go back to reference Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, Häcker A (2008) Systematic evaluation of a recently introduced 2-micron continuous-wave thulium laser for vaporesection of the prostate. J Endourol 22(5):1041–1045PubMedCrossRef Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, Häcker A (2008) Systematic evaluation of a recently introduced 2-micron continuous-wave thulium laser for vaporesection of the prostate. J Endourol 22(5):1041–1045PubMedCrossRef
11.
go back to reference Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Yi-Nan Zhang YN (2008) Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 53(2):382–389PubMedCrossRef Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Yi-Nan Zhang YN (2008) Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol 53(2):382–389PubMedCrossRef
12.
go back to reference Mattioli S, Muñoz R, Recasens R, Berbegal C, Cortada J, Urmeneta JM, Teichmann H (2008) Treatment of benign prostatic hyperplasia with the Revolix laser [Article in Spanish]. Arch Esp Urol 61(9):1037–1.043 Mattioli S, Muñoz R, Recasens R, Berbegal C, Cortada J, Urmeneta JM, Teichmann H (2008) Treatment of benign prostatic hyperplasia with the Revolix laser [Article in Spanish]. Arch Esp Urol 61(9):1037–1.043
13.
go back to reference Elzayat E, Habib E, Elhilali M (2006) Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175(4):1428–1432PubMedCrossRef Elzayat E, Habib E, Elhilali M (2006) Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol 175(4):1428–1432PubMedCrossRef
14.
go back to reference Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64(6):623–625PubMedCrossRef Parr NJ, Loh CS, Desmond AD (1989) Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br J Urol 64(6):623–625PubMedCrossRef
15.
go back to reference Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216PubMedCrossRef Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216PubMedCrossRef
16.
go back to reference Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, Ramon J (2002) The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 168(2):610–613PubMedCrossRef Dotan ZA, Mor Y, Leibovitch I, Varon D, Golomb J, Duvdevani M, Ramon J (2002) The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J Urol 168(2):610–613PubMedCrossRef
17.
go back to reference Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216PubMedCrossRef Descazeaud A, Robert G, Lebdai S, Bougault A, Azzousi AR, Haillot O, Devonec M, Fourmarier M, Saussine C, Barry-Delongchamps N, de la Taille A (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29(2):211–216PubMedCrossRef
18.
go back to reference Taylor K, Filgate R, Guo DY, Macneil F (2011) A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int. 108(Suppl 2):45–50PubMedCrossRef Taylor K, Filgate R, Guo DY, Macneil F (2011) A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int. 108(Suppl 2):45–50PubMedCrossRef
19.
go back to reference Hoffman RM, MacDonald R, Wilt TJ (2004) Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. (1):CD001987 Hoffman RM, MacDonald R, Wilt TJ (2004) Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. (1):CD001987
20.
go back to reference Larson TR (2002) Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology. 59:12–16PubMedCrossRef Larson TR (2002) Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology. 59:12–16PubMedCrossRef
21.
go back to reference Chung DE, Wysock JS, Lee RK, Melamed SR, Kaplan SA, Te AE (2011) Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol 186(3):977–981PubMedCrossRef Chung DE, Wysock JS, Lee RK, Melamed SR, Kaplan SA, Te AE (2011) Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol 186(3):977–981PubMedCrossRef
22.
go back to reference Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, Sulser T, Bachmann A (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51(4):1031–1041PubMedCrossRef Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, Sulser T, Bachmann A (2007) Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 51(4):1031–1041PubMedCrossRef
23.
go back to reference Bach T, Huck N, Wezel F, Hacker A, Gross AJ, Michel MS (2010) 70 vs 120 W thulium:yttrium-aluminium-garnet 2 micron continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex vivo evaluation. BJU Int 106(3):368–372PubMedCrossRef Bach T, Huck N, Wezel F, Hacker A, Gross AJ, Michel MS (2010) 70 vs 120 W thulium:yttrium-aluminium-garnet 2 micron continuous-wave laser for the treatment of benign prostatic hyperplasia: a systematic ex vivo evaluation. BJU Int 106(3):368–372PubMedCrossRef
24.
go back to reference Netsch C, Stoehrer M, Brüning M, Gabuev A, Bach T, Herrmann TR, Gross AJ (2013) Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. World J Urol. [Epub ahead of print] Netsch C, Stoehrer M, Brüning M, Gabuev A, Bach T, Herrmann TR, Gross AJ (2013) Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. World J Urol. [Epub ahead of print]
25.
go back to reference EAU Guidelines (2011) Laser-based treatments for bladder outlet obstruction (BOO) and benign prostatic enlargement (BPE). 29–34 EAU Guidelines (2011) Laser-based treatments for bladder outlet obstruction (BOO) and benign prostatic enlargement (BPE). 29–34
Metadata
Title
Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy
Authors
Luciano Macchione
Giuseppe Mucciardi
Alessandro Gali’
Antonina Di Benedetto
Salvatore Butticè
Carlo Magno
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 6/2013
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-013-0487-y

Other articles of this Issue 6/2013

International Urology and Nephrology 6/2013 Go to the issue